Raise GLP-1 Naturally
US$ 21.95
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66
Description
By combining ideas from endocrinology and scientific research, we can tell a full story
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3936995870949501299)
severe rash
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://polarispeptides.com/acd-cgi/img/v1/wp-content/uploads/2024/11/setmelanotide-10-mg-transparent-background1-1024x1024.png?metadata=none&width=800)
doi: 10.1080/13543784.2024.2377319 23
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://skinworksmed.com/wp-content/uploads/2025/04/Tirzepatide_vs_Semaglutide_in_torrance.png)
Excluded from this analysis were clinical trials involving animals or healthy humans, nonrandomized trials, RCTs shorter than 12 weeks, retrospective studies, pooled analyses of clinical trials, conference proceedings, letters to editors, case reports, and articles that lacked relevant data on the outcomes of interest
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://www.transformyou.com/hubfs/Screenshot%202024-02-21%20at%2012.21.41%20PM.png)
Members get access to: Clinicians trained in obesity medicine, self-paced lifestyle change program designed by doctors, psychologists, and behavioral scientists & our exclusive in-app community
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://healingmaps.com/wp-content/uploads/2026/04/semaglutide-vs-tirzepatide-infographic.webp)
A 2 mL vial at 10 mg/mL contains 20 mg total
![setmelanotide vs tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Among participants 4 to 66](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-025-03913-2/MediaObjects/41591_2025_3913_Fig1_HTML.png)